AggreWell™400

简单可重复性地制备拟胚体和球体的微孔培养板

只有 %1 左

率先评论此产品

¥1,100.00

产品号 #（选择产品）

产品号 #34411_C

简单可重复性地制备拟胚体和球体的微孔培养板

产品组分包括

AggreWell™400 24孔板

1块板（产品号#34411）
5块板（产品号#34415）

AggreWell™400 6孔板

1块板（产品号#34421）
5块板（产品号#34425）

AggreWell™400 24孔板套装（产品号#34450）

2 x 24孔板
1瓶抗粘附冲洗液（产品号#07010）

AggreWell™400 6孔板套装（产品号#34460）

2 x 6孔板
1瓶抗粘附冲洗液（产品号#07010）

立即询价

总览

AggreWell™细胞培养板提供了一种简单、标准化的方法来生成细胞聚集体，包括拟胚体（EBs）和球体。使用AggreWell™板生成的EBs和球体在大小和形状上是均一的，并且在实验内和实验间均表现出良好的均一性。新一代改进版AggreWell™板兼容多种细胞类型，包括胚胎干细胞、诱导多能干细胞、肿瘤细胞等，其增强的光学特性确保成像清晰无杂质。注意：为获得最佳的EB和球状体形成效果，需配合使用AggreWell™抗粘附冲洗液。

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

文献 (22)

Identification of a core transcriptional program driving the human renal mesenchymal-to-epithelial transition Ng-Blichfeldt et al. Developmental cell 2024 Feb

Abstract

During kidney development,nephron epithelia arise de novo from fate-committed mesenchymal progenitors through a mesenchymal-to-epithelial transition (MET). Downstream of fate specification,transcriptional mechanisms that drive establishment of epithelial morphology are poorly understood. We used human iPSC-derived renal organoids,which recapitulate nephrogenesis,to investigate mechanisms controlling renal MET. Multi-ome profiling via snRNA-seq and ATAC-seq of organoids identified dynamic changes in gene expression and chromatin accessibility driven by activators and repressors throughout MET. CRISPR interference identified that paired box 8 (PAX8) is essential for initiation of MET in human renal organoids,contrary to in vivo mouse studies,likely by activating a cell-adhesion program. While Wnt/β-catenin signaling specifies nephron fate,we find that it must be attenuated to allow hepatocyte nuclear factor 1-beta (HNF1B) and TEA-domain (TEAD) transcription factors to drive completion of MET. These results identify the interplay between fate commitment and morphogenesis in the developing human kidney,with implications for understanding both developmental kidney diseases and aberrant epithelial plasticity following adult renal tubular injury.

View publication

A microfluidic platform integrating functional vascularized organoids-on-chip C. Quintard et al. Nature Communications 2024 Feb

Abstract

The development of vascular networks in microfluidic chips is crucial for the long-term culture of three-dimensional cell aggregates such as spheroids,organoids,tumoroids,or tissue explants. Despite rapid advancement in microvascular network systems and organoid technologies,vascularizing organoids-on-chips remains a challenge in tissue engineering. Most existing microfluidic devices poorly reflect the complexity of in vivo flows and require complex technical set-ups. Considering these constraints,we develop a platform to establish and monitor the formation of endothelial networks around mesenchymal and pancreatic islet spheroids,as well as blood vessel organoids generated from pluripotent stem cells,cultured for up to 30 days on-chip. We show that these networks establish functional connections with the endothelium-rich spheroids and vascular organoids,as they successfully provide intravascular perfusion to these structures. We find that organoid growth,maturation,and function are enhanced when cultured on-chip using our vascularization method. This microphysiological system represents a viable organ-on-chip model to vascularize diverse biological 3D tissues and sets the stage to establish organoid perfusions using advanced microfluidics. Subject terms: Stem-cell biotechnology,Tissue engineering,Biomedical engineering,Induced pluripotent stem cells,Microfluidics

View publication

Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells S. Kaur et al. Frontiers in Cell and Developmental Biology 2024 Mar

Abstract

Signal regulatory protein-α (SIRPα,SHPS-1,CD172a) expressed on myeloid cells transmits inhibitory signals when it engages its counter-receptor CD47 on an adjacent cell. Elevated CD47 expression on some cancer cells thereby serves as an innate immune checkpoint that limits phagocytic clearance of tumor cells by macrophages and antigen presentation to T cells. Antibodies and recombinant SIRPα constructs that block the CD47-SIRPα interaction on macrophages exhibit anti-tumor activities in mouse models and are in ongoing clinical trials for treating several human cancers. Based on prior evidence that engaging SIRPα can also alter CD47 signaling in some nonmalignant cells,we compared direct effects of recombinant SIRPα-Fc and a humanized CD47 antibody that inhibits CD47-SIRPα interaction (CC-90002) on CD47 signaling in cancer stem cells derived from the MDA-MB- 231 triple-negative breast carcinoma cell line. Treatment with SIRPα-Fc significantly increased the formation of mammospheres by breast cancer stem cells as compared to CC-90002 treatment or controls. Furthermore,SIRPα-Fc treatment upregulated mRNA and protein expression of ALDH1 and altered the expression of genes involved in epithelial/mesenchymal transition pathways that are associated with a poor prognosis and enhanced metastatic activity. This indicates that SIRPα-Fc has CD47-mediated agonist activities in breast cancer stem cells affecting proliferation and metastasis pathways that differ from those of CC-90002. This SIRPα-induced CD47 signaling in breast carcinoma cells may limit the efficacy of SIRPα decoy therapeutics intended to stimulate innate antitumor immune responses.

View publication

View All Publications

AggreWell™400

产品号 #34415

产品号 #34411

产品号 #34450

产品号 #34425

产品号 #34421

产品号 #34460

产品号 #（选择产品）

产品号 #34411_C

产品组分包括

总览

产品说明书及文档

应用领域

相关材料与文献

Request Pricing

更多信息

Scientists Helping Scientists™

AggreWell™400

产品号 #34415

产品号 #34411

产品号 #34450

产品号 #34425

产品号 #34421

产品号 #34460

产品号 #（选择产品）

产品号 #34411_C

产品组分包括

总览

产品说明书及文档

应用领域

相关材料与文献

技术资料 (14)

文献 (22)

Abstract

Abstract

Abstract

Request Pricing

更多信息

欢迎您关注STEMCELL Technologies的微信公众平台